FDA sends let­ter to No­var­tis over Kym­ri­ah man­u­fac­tur­ing safe­ty con­cerns

The FDA on Tues­day re­leased a new un­ti­tled let­ter, sent in Au­gust to No­var­tis, af­ter the agency’s in­spec­tors found new and sig­nif­i­cant is­sues with how Kym­ri­ah, the first-ever FDA-ap­proved CAR-T cell ther­a­py, is made at the com­pa­ny’s Mor­ris Plains, NJ, site.

While the FDA said it al­ready is­sued a Form 483 out­lin­ing some of its ear­ly thoughts on the late 2022 in­spec­tion, and re­ceived re­spons­es from No­var­tis, the agency says it’s now iden­ti­fied “ad­di­tion­al sig­nif­i­cant de­vi­a­tions” up­on fur­ther re­view of the in­for­ma­tion col­lect­ed dur­ing that in­spec­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER